Lian Hua Qing Wen sold out of stock Yiling Pharmaceutical urgently hired short-term workers! The stock price has been bullish for five consecutive days.

After two hot searches of "selling out of stock" and "recruiting general workers", the share price of Yiling Pharmaceutical has been bullish for five consecutive days.

As the sole manufacturer of Lianhua Qingwen Capsule, Yiling Pharmaceutical, headquartered in Shijiazhuang, has become the focus of market pursuit. As of the close of November 18th, Yiling Pharmaceutical led the Chinese medicine sector with a weekly increase of 48.29%. Looking back on the performance of Yiling Pharmaceutical in one week, we have gained three daily limit this week, and set a new record high with the closing price of 46.28 yuan, with a total market value of 77.32 billion yuan.

At the same time, Yiling Pharmaceutical announced that it had accumulated 26.8% deviation in closing price increase for three consecutive trading days on November 14th, 15th and 16th, 222. In response to the abnormal fluctuations in the stock, the company said that it did not disclose major news. Recently, the company's operating conditions and internal and external operating environment have not changed significantly, and the controlling shareholder and actual controller did not buy or sell the company's shares during the period of abnormal stock fluctuations.

Two Hot Searches

Recently, "Shijiazhuang Lianhua Qingwen Capsule is out of stock" was hot searched in Weibo. This "out-of-stock" rumor was caused by an article on the micro-signal of Cailian on the evening of the 14th: "Lianhua Qingyi" sells explosively! Yiling pharmaceutical headquarters was once out of stock, and employees had to queue up for internal purchases. According to the original report, the staff of a local chain pharmacy in Shijiazhuang revealed that "there are many people who bought Lianhua Qingwen capsules these two days. Two boxes of goods were just transferred this morning, and now they are basically sold out (48 boxes in one box)."

On the evening of November 15th, the relevant person of Yiling Pharmaceutical said, "Yiling Pharmaceutical has been doing a series of work to improve its production capacity in recent two years, and its production capacity has been greatly improved. The company's production plan is "fixed production by sales", and will adjust the production plan in time according to market demand to ensure market supply. The company's production is basically unaffected, and the current sales situation is all normal. As for the need to queue up for purchase within the company, it is because the in-house purchase has been changed from the original traditional self-delivery to online express delivery, and the time has been extended compared with the self-delivery. "

On the afternoon of November 16th, "Yiling Pharmaceutical Recruits a Large Number of General Workers" was listed on Weibo Hot Search, and its ranking kept rising. According to Cailian News Agency, since November 14th, the Shijiazhuang factory of Yiling Pharmaceutical Co., Ltd. has started to recruit short-term workers for 1-3 months to increase the production of Lianhua Qingwen drugs. It is estimated that the total recruitment will be more than 1,, which is limited to male workers. It is expected that the recruitment will be completed this week. Short-term workers are mainly engaged in drug packaging, cleaning and cutting, and they work in shifts of 24 hours a day. Man Qin's salary is 18 yuan/day, and the company includes room and board, with four days off every month and closed management. Living in three-star wine requires isolation for three days.

On November 17th, WeChat official account, the "Daxing Employment Platform", released the recruitment information. Beijing Yiling Pharmaceutical Co., Ltd. urgently hired 2 production operators, mainly engaged in the relevant operation links of Chinese medicine production, with the treatment of 4,-6, yuan/month, five insurances and one gold, free accommodation, free lunch (breakfast in 3 yuan, dinner in 5 yuan), birthday benefits, and wireless internet in the dormitory.

According to the recruitment article, Beijing Yiling Pharmaceutical Co., Ltd. is located in the biomedical industrial base of Zhongguancun Science Park, Daxing District, Beijing, and its main business is the research, development, production and sales of new Chinese medicine and health care products with characteristic patents. Lianhua Qingwen Granule, the company's main product, is listed as the recommended drug in the Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial 4th/5th/6th/7th/8th/9th Edition). Tianyancha APP shows that Beijing Yiling Pharmaceutical is a 1% holding subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd..

For the above situation, Yiling Pharmaceutical explained that Lianhua Qingwen, as a representative Chinese patent medicine to deal with major public health incidents, has been included in the diagnosis and treatment plans or guidelines/recommended drugs for infectious public health incidents such as influenza A, influenza B, avian influenza and COVID-19 issued by National Health Commission and state administration of traditional chinese medicine for 3 times since its listing in 23.

The annual income is 4 billion yuan

Lianhua Qingwen Capsule (Granule) is the first approved therapeutic drug for COVID-19 in the world, and in April 22, the indication of "novel coronavirus light and common" was added. In March, 222, in the newly published "novel coronavirus Diagnosis and Treatment Plan (Trial Ninth Edition)", Lianhua Qingwen Capsule (Granule) was not only listed as a recommended drug in the medical observation period of traditional Chinese medicine, but also as a light and ordinary recommended drug in the clinical treatment period (confirmed cases).

In the past 2 years, Lianhua Qingwen has become one of the most innovative traditional Chinese medicines in China. Lianhua Qingwen has been recommended by National Health Commission, state administration of traditional chinese medicine and the Society for 3 times, and it has been included in the plans of Influenza Diagnosis and Treatment (218, 219 and 22 editions), Influenza A (H1N1), Traditional Chinese Medicine Prevention and Treatment of Influenza B, and Human Infection with H7N9 Avian Influenza, and has become a representative drug in China to deal with public health incidents of viral infectious diseases.

As of the first three quarters of 222, the anti-cold products of Lianhua Qingwen series have surpassed cardiovascular and cerebrovascular products and become the largest business segment of Yiling Pharmaceutical. From 213 to 221, the company's net profit successfully achieved "nine consecutive increases". Since the outbreak, the revenue of Lianhua Qingwen medicine has exceeded 4 billion yuan for two consecutive years, accounting for more than 4% of the total revenue, and the gross profit margin is as high as 7%.

Since the beginning of this year, Lianhua Qingwen medicine has continued to exert its strength. In the first three quarters, the company has achieved a net profit of 1.414 billion yuan, exceeding the 1.344 billion yuan of last year. On October 28th, Ray Wu, Director General of Yiling Pharmaceutical Co., Ltd. said at the performance briefing that in the first three quarters of this year, due to its special product attributes of treating COVID-19, influenza and cold, the revenue of Lianhua Qingwen still achieved year-on-year growth at a higher base in 221.

In addition, the reporter searched the financial report and found that the sales revenue of Lianhua Qingwen has become an important component of Yiling Pharmaceutical's performance growth. From 217 to 221, the sales revenue of anti-cold drugs represented by Lianhua Qingwen drugs was 651 million yuan, 1.25 billion yuan, 1.73 billion yuan, 4.256 billion yuan and 4.18 billion yuan respectively, accounting for 15.96%, 25.3%, 29.24%, 48.46% of the total revenue respectively.

According to the share of medical terminal products, the data in Minenet shows that Lianhua Qingwen products ranked first in the public medical market in 221, and its market share was as high as 41.78%, far exceeding the 7.31% of the second Shuanghuanglian oral liquid. In the retail terminal, in the first half of 222, Lianhua Qingwen Capsule also surpassed Ganmaoling Granules, ranking first in the sales of cold medicine/heat-clearing.

In this regard, Yiling Pharmaceutical said that Lianhua Qingwen has played an active role in the prevention and control of COVID-19 epidemic in China, and it has been widely used in designated hospitals, shelter hospitals, isolated populations, close contact and sub-close contact populations in various provinces and cities. In addition, eight kinds of drugs in Yiling Pharmaceutical, including Lianhua Qingwen drugs, also entered the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 221.

Southwest Securities pointed out that the R&D policy of innovative Chinese medicine is favorable, and Yiling Pharmaceutical has abundant varieties. Strengthen the construction of the evidence system of Chinese medicine registration and evaluation based on the combination of Chinese medicine theory, human experience and clinical trial. With the recent release of NMPA's Guiding Principles for Clinical R&D of New Compound Preparations of Traditional Chinese Medicine (Trial), the R&D decision-making or registration application of new compound preparations of traditional Chinese medicine may usher in an upsurge. The company has six drugs under research in the field of innovative drugs of traditional Chinese medicine, and this policy will accelerate the listing of more than 1 kinds of preparations in the company's reserve hospitals.

Northeast Securities believes that the annual performance of Yiling Pharmaceutical can be expected when the high-incidence season of influenza comes in winter. In the same period last year, Q4 was restricted by four kinds of drugs. The current drug control has been obviously relaxed compared with Q4 last year, and Q4 alone is expected to achieve high growth. At the same time, cardiovascular and cerebrovascular products continue to recover marginally, and the annual performance is expected to achieve high economic growth. In addition, the company's two new drugs, Jieyu Chufan Capsule and Yishen Yangxin Anshen Tablet, passed the preliminary form review of medical insurance catalogue adjustment this year and are expected to eventually enter the medical insurance catalogue list.